Solid Biosciences Q3 EPS $(1.05) Beats $(1.19) Estimate
Portfolio Pulse from Benzinga Newsdesk
Solid Biosciences reported Q3 losses of $(1.05) per share, beating the analyst consensus estimate of $(1.19) by 11.76 percent. This is a 61.25 percent increase over losses from the same period last year.
November 08, 2023 | 10:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Solid Biosciences reported better than expected Q3 losses, which may positively impact the stock in the short term.
Solid Biosciences reported a smaller loss than expected for Q3, beating analyst estimates by 11.76%. This is a significant improvement over the same period last year, which could lead to increased investor confidence and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100